Empowering dialysis users and caregivers
Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Professional dialysis recruitment| Rockwell Medical, Inc. Analyst Rating Update - American Trade Journal |
 |
 |
|
Rockwell Medical, Inc. (NASDAQ:RMTI) has received a short term rating of hold from research analysts at Zacks with a rank of 3. The company has been rated an average of 2.55 by 6 Wall Street Analysts. 3 analysts have added the shares in their list of strong buys. 1 analysts have advised hold. 2 has rated the company as strong sell. Many analysts have commented on the company rating. Equity Analysts at the Brokerage Firm, Bank of America, reinstates their rating on the shares of Rockwell Medical, Inc. (NASDAQ:RMTI). Bank of America has a Neutral rating on the shares. The rating by the firm was issued on July 8, 2015. Rockwell Medical, Inc. (NASDAQ:RMTI) stock has received a short term price target of $ 15 from 6 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $8.15. The higher estimate of target price is $26 , while the lower price target estimate is $4 Rockwell Medical, Inc. (NASDAQ:RMTI) witnessed a decline in the market cap on Monday as its shares dropped 0.08% or 0.01 points. After the session commenced at $12.52, the stock reached the higher end at $12.65 while it hit a low of $12.05. With the volume soaring to 736,811 shares, the last trade was called at $12.64. The company has a 52-week high of $18.8999. The company has a market cap of $635 million and there are 50,223,000 shares in outstanding. The 52-week low of the share price is $8.095. Rockwell Medical, Inc. has lost 10.29% in the last five trading days and dropped 29.82% in the last 4 weeks. Rockwell Medical, Inc. is up 20.96% in the last 3-month period. Year-to-Date the stock performance stands at 22.96%. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the CEO of Rockwell Medical, Inc., Chioini Robert L, had purchased 4,910 shares in a transaction dated on August 14, 2015. The transaction was executed at $11.96 per share with total amount equaling $58,724. Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patients bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol. |
